Member Info for Trickymatters

Fourfigures, I am not saying it's Ok to have a go at you. I am saying making nasty comments about some-one because they are gay is totally pathetic. It's the 21st century mate.

Fourfigures, what the fxxk is wrong with you? Stop making cretinous comments about Regulator. Either challenge him with a real argument or leave it out. No-one is impressed with your ignorant digs. You're an embarrassment to this board.

Great news today -79% efficacy confirmed and first dosage for final stage phase 3 trials. Fast tracked in the official UK and US medical authority schemes for a treatment to reduce mortality and support faster recovery. First dosing on the US trials to start in 2 weeks. They will attract huge investment from Operation Warp Speed as soon as they release interim results if not before. What's not to like? Richard Marsden should get knighted. Oh wait...

What is true is that Mologic are starting fast track trials on the official FDA fast track program exactly as it says in the tweet Hani1. As we were informed by RNS by ODX. Ffs. Derampers are turning into trolls now.

Thanks Oxford. Ah that makes sense. Well according to the YouTube video from the Activ2 trials the Synairgen trial is due to start in a fortnight. So we might get an RNS before then or on first dosing again? Exciting.

Thx v much k-Mac and Oakleaf.

So the Activ 2 trial is starting in the US in a fortnight. Sorry to ask dumb questions. I only jumped in here before Xmas so still catching up. Anyone know when the Warp Speed trials start?

Although it's broadly very positive coverage and the fact that they have got it on their 24 hour news channel isn't too shabby. Bit of a devil's advocate on my own argument now. Lol.

Just watched it again. The woman sounding the obligatory note of caution, using the example of Trump's favourite drug- not the bleach, the other one (!?)- seems like a bit of thoughtless dedication to the principle of devil's advocate. It does annoy me when the media do that. You know what? You can get excited about 79% efficacy! Results remained stable over phase 1 and 2 trials. My guess is the US media will get excited in 2 weeks when SNG start the Activ2 trials.

Is massively behind schedule. Over 80s are not going to travel to a vaccine centre in the middle of the night. 24 hour offer is not going to fly. 145,000 done yesterday because they still don't have sufficient volume to do 2 million a week. A government spokesman told the Today programme on radio 4 just now that the aspiration 'seems to be ' emerging to vaccinate all adults and that we should be in a position to do so by the end of the year. It's becoming clear that the aspiration for 15 million by mid February is nebulous. The vaccine plan puts mass testing centre stage for helping us out of restrictions once we have vaccinated all the most vulnerable.
3 huge contracts on bid stats for antibody tests. Only 2 weeks to the deadline. No-one else has an antibody lft test which has been evaluated and approved for government purchase. Not long to jump in at these prices.

G8 video pmjh, so we expect the SNG Activ2 trial to start in 2 weeks. The panel of doctors say that they are excited about it and they will be back to discuss it in more detail. That should definitely deserve another RNS wouldn't you think?

My guess is it will be split between a few providers. I think we are could be in the mix- we'll see how far Mologic have progressed with the antigen lft soon enough. Based on the fact that results to date are very good and Mologic and Avacta are in the mix for relevant listed suppliers and both are UK based- which is said to be a government aspiration. If someone like Healgen get a bite they will need a manufacturing partner. So there's more possibilities than meets the eye in this environment.

Is all over Deeks on Twitter. Dr Michael Mina is a big advocate for lfts as the way to manage the pandemic- speed is what will help us get the virus down. Because people get results straight away they are more serious and focused on self isolation. He's all over the press in the US too. He's also picked Deeks up on his mad stats and weak appreciation of his public health implications of trying to rely on PCR to keep numbers down. Virus moves too fast for PCR. Nice to see the argument being made by someone with massive kudos in the field and he's not sparing Deeks feelings! Lol.

As soon as the RNS for first dosage lands, we'll get some more institutional investors buying in. Phase 3 trials do fail sometimes but not when the phase 2 has results at 73% efficacy. Not long till we get to a new level imo. And with the FTSE going flat now that the market has bottomed onto a double dip, covid tinged recession, we will build from there quickly too imho.
GLA.

And it's Innova he's criticising.

Deeks again. He looks a bit more mad every time he's on TV. Judicial review ain't happening. The GLP didn't raise 40% of what they needed.

The RNS on 24th December advised us that the full report on Mologic's antigen test from Liverpool School of Tropical Medicine is due very soon. We already know that LSTM thought highly of the test. Interesting that it's LTSM who are helping the government as independent, academic partners, to develop the surveillance methods for the vaccine efficacy. This will include all key demographics, every group with underlying health issues. It aims to answer key questions such as whether the vaccine is still transmissable and how long immunity lasts as well as the level of protection that is afforded in real life settings.
Those vaccinated will be amongst the groups who are monitored through the SIREN program for health workers and a separate study for care workers. PCRs and lfts will be used quarterly and fortnightly with a recommendation for twice weekly lfts (page 18, section 3, vaccine plan) and in the surveillance report regular antibody lfts- 'we are examining how we can make use of antibody tests' (page 14, section 5).
A big emphasis on surveillance. We are first out of the block. We have a responsibility to learn as much as we can but most of all we have to defeat the virus for everyone's sake. The vaccine plan also makes it clear we will be using mass testing to support us to emerge from the restrictions. It's hard to work out what's going on with the MHRA. One thing's for sure we are best positioned to win all the big contracts for antibody tests. They want both types of tests. Mologic's test is very sensitive and will pick up 3 antibodies. The ABC19 test will recognise high levels of antibodies sufficient to confer immunity.
£285 million worth of antibody contracts. £85 million worth has actually got our name on it.

Twatcher, it's nobody's job to teach you to read. The fact that you say you can't see what is in front of you on page 19 exactly as I have quoted just means that you are attempting to manipulate the board. As you have done before.

Can I ask a favour from all investors who are capable of reading? iPhone has shared something that is factually incorrect. The new delivery plan specifically recognises lfts role in surveillance (page 19) and the surveillance strategy as lots of us have recognised, discusses surveillance plans so far. So if you disagree with him, can you change the header for the thread? Thx v much.

Health workers being tested with PCRs once a fortnight and lateral flow tests twice a week. Page 19.
The Surveillance Strategy explains that alongside the SIREN program ( health workers) every demographic and people with every type of additional health needs will be tracked. We need to understand how long immunity lasts and whether the vaccine prevents transmission.
And meanwhile pretty much every local authority will receive lateral flow tests to help reduce the spread of the virus.
Contract deadlines for antibody tests are this week and through to January 31st. Delivery dates from February 1st- February 14th. And one contract has already been awarded to the RTC.
ODX are tweeting away today. News on Mologic's antigen lft test evaluation results, tech transfer and sales for the Omega Visitect antibody lft is coming this month. Exciting! GLA.